Klaus Metzeler, MD obtained his MD from Technical University, Munich, Germany in 2005 and trained as a hemato-oncologist at the University of Munich. He pursued a research fellowship in molecular cancer genetics at the Ohio State University Comprehensive Cancer center, focusing on prognostic and predictive biomarkers in Acute Myeloid Leukemia. From 2016, he was an attending physician, research group leader, and head of the hematological cytomorphology lab at the University of Munich. In 2021, he became professor of translational hematology at the University of Leipzig, Germany, and head of the hematological diagnostics laboratory. His clinical focus is diagnosis and treatment of myeloid malignancies, and his current research interests include translational biomarker studies in myeloid neoplasms, genetics and clinical relevance of clonal hematopoiesis, and quality of life in AML survivors.